Kalaco
was formed in November 2001 and immediately
began efforts to raise the money necessary
to bring the Nexalin™ technology
to the world market in a manner that
is atypical for a medical device manufacturing
company. The importance of the technology
demands this advanced business approach.
The Nexalin technology is an evolution
of 25+ years of research.
Kalaco currently has clearance in the United
States for Anxiety, Depression, and Insomnia.
Other intended uses are approved in other
countries, but not yet in the United States
and require investigation and FDA market authorization
before the Nexalin™ technology can be
offered for those uses.
